-
Abstract Number: 2431
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
-
Abstract Number: 2432
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
-
Abstract Number: 2433
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
-
Abstract Number: 2434
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
-
Abstract Number: 2435
Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 2436
Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
-
Abstract Number: 2437
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
-
Abstract Number: 2438
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
-
Abstract Number: 2439
Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
-
Abstract Number: 2440
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
-
Abstract Number: 2441
Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis
-
Abstract Number: 2442
Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study
-
Abstract Number: 2443
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
-
Abstract Number: 2444
Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
-
Abstract Number: 2445
Effects of Aminaphtone on TGF-beta1 Serum Concentration as Concomitant Treatment to Standard Therapy in Systemic Sclerosis Patients: A Pilot Study
- « Previous Page
- 1
- …
- 162
- 163
- 164
- 165
- 166
- …
- 181
- Next Page »